• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Daiichi Sankyo Ltd ADR (OP: DSNKY )

    31.83 -0.24 (-0.75%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Daiichi Sankyo Ltd ADR

    < Previous 1 2 Next >
    Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
    AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free... 
    Via Benzinga
    Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
    Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... 
    Via Benzinga
    AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
    AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to... 
    Via Benzinga
    DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024
    Daiichi Sankyo Co just reported results for the first quarter of 2024. 
    Via InvestorPlace
    Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
    "As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say. 
    Via Benzinga
    Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
    Via Benzinga
    Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
    Via Benzinga
    Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
    Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises... 
    Via Benzinga
    Exposures Product Safety
    The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
    Undervalued Nasdaq 100 stocks may not be as rare as hen's teeth but not quite so plentiful amid a raging bull market. 
    Via InvestorPlace
    FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
    The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The... 
    Via Benzinga
    Exposures Product Safety
    Why Is AstraZeneca Stock Trading Lower On Tuesday?
    AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance. 
    Via Benzinga
    DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023
    Daiichi Sankyo Co just reported results for the third quarter of 2023. 
    Via InvestorPlace
    Double Good News For AstraZeneca's Breast Cancer Drugs
    Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer. 
    Via Benzinga
    AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
    FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal... 
    Via Benzinga
    Exposures Product Safety
    What's Going On With Pfizer Stock Today?
    Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues. 
    Via Benzinga
    Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares are trading lower on Wednesday after the company announced a $125 million amendment to the collaboration with Japanese pharma company Daiichi Sankyo... 
    Via Benzinga
    Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
    Japanese stocks are gaining favor among I-banks and sport attractive valuations; here are 3 stocks with low P/B that have outperformed and could generate shareholder wealth. 
    Via Benzinga
    Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
    In due time, its new partnership with Daiichi Sankyo could be massive. 
    Via The Motley Fool
    Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
    AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:  
    Via Benzinga
    AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
    Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria 
    Via Benzinga
    FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
    The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in 
    Via Benzinga
    Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
    World's Largest Psychedelics Conference Boasts 12K Attendees 
    Via Benzinga
    AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
    AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung... 
    Via Benzinga
    Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
    Australia biotech startup Psylo has inked a sponsored research agreement with global Japanese pharmaceutical company Daiichi Sankyo (OTCMKTS: DSNKY) toward advancing antidepressant psychiatric... 
    Via Benzinga
    AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
    Via Benzinga
    Is Gilead Sciences a Good Stock to Buy Now?
    Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward. 
    Via The Motley Fool
    AstraZeneca’s Next “Wonder Drug”
    Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential to become a key... 
    Via Talk Markets
    AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
    Via Benzinga
    AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
    Via Benzinga
    European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
    Via Benzinga
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.